Kodiak Sciences Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 03:30PM GMT
Anupam Rama - JP Morgan Chase & Co, Research Division - VP and Analyst

Okay. We'll go ahead and get started. I've been told from the audience that my introduction for this hasn't changed in 10 years. But I want to welcome everybody to the Tuesday morning of the 2020, JP Morgan Health Care conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JP Morgan. Matt Bannon and Tessa Romero from the team are joining me. Our first presenting company of the day is Kodiak, and presenting on behalf of the company is CEO, Victor Perlroth. Victor?

Victor Perlroth - Kodiak Sciences Inc. - Co-Founder, Chairman, CEO & President

Thank you, Anupam. I'm Victor Perlroth, the CEO of Kodiak Sciences. It's my pleasure to be here. Just a quick note on our forward-looking statements before we dive in.

Our goal at Kodiak is to develop the best next-generation therapeutics for high-prevalence retinal diseases using our antibody biopolymer conjugate, or ABC Platform. And KSI-301 is our lead molecule. It's our anti-VEGF ABC and the data that we're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot